{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Palmer AC"],"funding":["NCI","NCI NIH HHS"],"pagination":["368-377"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9068233"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["28(2)"],"pubmed_abstract":["Purpose
Combinations of immune-checkpoint inhibitors (ICI) with other cancer therapies have been approved for advanced cancers in multiple indications, and numerous trials are under way to test new combinations. However, the mechanisms that account for the superiority of approved ICI combinations relative to their constituent monotherapies remain unknown.Experimental design
We analyzed 13 phase III clinical trials testing combinations of ICIs with each other or other drugs in patients with advanced melanoma and lung, breast, gastric, kidney, and head and neck cancers. The clinical activity of the individual constituent therapies, measured in the same or a closely matched trial cohort, was used to compute progression-free survival (PFS) curves expected under a model of indep"],"journal":["Clinical cancer research : an official journal of the American Association for Cancer Research"],"pubmed_title":["Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors."],"pmcid":["PMC9068233"],"funding_grant_id":["U54-CA225088","R37 CA258829","K08 CA222663","U54 CA225088","K08-CA222663","R37-CA258829"],"pubmed_authors":["Izar B","Sorger PK","Hwangbo H","Palmer AC"],"additional_accession":[]},"is_claimable":false,"name":"Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors.","description":"Purpose
Combinations of immune-checkpoint inhibitors (ICI) with other cancer therapies have been approved for advanced cancers in multiple indications, and numerous trials are under way to test new combinations. However, the mechanisms that account for the superiority of approved ICI combinations relative to their constituent monotherapies remain unknown.Experimental design
We analyzed 13 phase III clinical trials testing combinations of ICIs with each other or other drugs in patients with advanced melanoma and lung, breast, gastric, kidney, and head and neck cancers. The clinical activity of the individual constituent therapies, measured in the same or a closely matched trial cohort, was used to compute progression-free survival (PFS) curves expected under a model of indep","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jan","modification":"2026-07-14T16:45:10.165Z","creation":"2026-06-21T03:07:41.307Z"},"accession":"S-EPMC9068233","cross_references":{"pubmed":["35045958"],"doi":["10.1158/1078-0432.CCR-21-2275"]}}